ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast
ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced results from the trastuzumab emtansine Phase III EMILIA trial conducted by Roche.